Paper41014398
Do the therapeutic vaccines hold hope for the treatment of hepatitis B?
Yan Q and 3 others. Hepatol Int, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Do the therapeutic vaccines hold hope for the treatment of hepatitis B? Papers, record 41014398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41014398
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Hepatitis B Vaccines | Major topic |
| Humans | |
| Antiviral Agents | |
| Hepatitis B virus |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82270626 | National Natural Science Foundation of China | PubMed | ||
| 81870417 | National Natural Science Foundation of China | PubMed | ||
| 82070605 | National Natural Science Foundation of China | PubMed | ||
| 2022CR63 | Peking University First Hospital | PubMed | ||
| 2025SF052 | Peking University First Hospital | PubMed | ||
| 2020A03004-3 | Science and Technology Department of Xinjiang Uygur Autonomous Region | PubMed | ||
| 2024-zz-102 | Beijing postdoctoral research activities innovation research and development fund | PubMed |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19697028 | Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. | Ann Hematol | 2010 | https://conductscience.org/library/papers/19697028 | PubMed |
| 2 | 34661089 | Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. | JHEP Rep | 2021 | https://conductscience.org/library/papers/34661089 | PubMed |
| 3 | 34629819 | Treatment of hepatitis B virus infection in children and adolescents. | World J Gastroenterol | 2021 | https://conductscience.org/library/papers/34629819 | PubMed |
| 4 | 28735813 | Atypical memory B cells in human chronic infectious diseases: An interim report. | Cell Immunol | 2017 | https://conductscience.org/library/papers/28735813 | PubMed |
| 5 | 24555998 | Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. | Gut | 2015 | https://conductscience.org/library/papers/24555998 | PubMed |
| 6 | 25858855 | Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. | Vaccine | 2015 | https://conductscience.org/library/papers/25858855 | PubMed |
| 7 | 25045824 | Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. | Vaccine | 2014 | https://conductscience.org/library/papers/25045824 | PubMed |
| 8 | 30133478 | Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). | PLoS One | 2018 | https://conductscience.org/library/papers/30133478 | PubMed |
| 9 | 30982722 | Hepatitis B virus infection in children and adolescents. | Lancet Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30982722 | PubMed |
| 10 | 22884884 | Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. | Antiviral Res | 2012 | https://conductscience.org/library/papers/22884884 | PubMed |
| 11 | 34804072 | Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. | Front Immunol | 2021 | https://conductscience.org/library/papers/34804072 | PubMed |
| 12 | 11244031 | Noncytolytic control of viral infections by the innate and adaptive immune response. | Annu Rev Immunol | 2001 | https://conductscience.org/library/papers/11244031 | PubMed |
| 13 | 26058465 | Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. | Chin J Cancer | 2015 | https://conductscience.org/library/papers/26058465 | PubMed |
| 14 | 28127204 | Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28127204 | PubMed |
| 15 | 38808361 | Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. | Clin Mol Hepatol | 2024 | https://conductscience.org/library/papers/38808361 | PubMed |
| 16 | 36851208 | HBV and HCV Infection in Children and Adolescents. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36851208 | PubMed |
| 17 | 37243066 | Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/37243066 | PubMed |
| 18 | 30930022 | Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30930022 | PubMed |
| 19 | 18031872 | Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. | Vaccine | 2007 | https://conductscience.org/library/papers/18031872 | PubMed |
| 20 | 37791379 | HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV. | JHEP Rep | 2023 | https://conductscience.org/library/papers/37791379 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42931375 | Assessing the Status of and Impediments to Achieving the WHO Goal to Eliminate Viral Hepatitis B by 2030: A Scoping Review. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42931375 | PubMed |
| 42829048 | Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach. | Virus Res | 2026 | https://conductscience.org/library/papers/42829048 | PubMed |
| 42769254 | FBXO11 and FBXO32 are associated with TRAF3-TBK1-IRF3 signaling components in chronic hepatitis B: evidence from clinical samples and preliminary mechanistic studies. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42769254 | PubMed |
| 42506615 | Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506615 | PubMed |
| 42347630 | Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42347630 | PubMed |
| 42328176 | Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42328176 | PubMed |
| 41828677 | Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828677 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41014398
GET https://conductscience.org/api/papers/v1/41014398/references?page=2